Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PTPRJ |
| Gene Name: | PTPRJ |
| Protein Full Name: | Receptor-type tyrosine-protein phosphatase eta |
| Alias: | CD148; CD148 antigen; Density-enhanced phosphatase 1; DEP1; EC 3.1.3.48; HPTP eta; HPTPeta; Human density enhanced phosphatase-1; Protein tyrosine phosphatase, receptor type, J; Protein-tyrosine phosphatase receptor type J; Receptor-type tyrosine-protein phosphatase eta; R-PTP-ETA; SCC1 |
| Mass (Da): | 145941 |
| Number AA: | 1337 |
| UniProt ID: | Q12913 |
| Locus ID: | 5795 |
| COSMIC ID: | PTPRJ |
| Gene location on chromosome: | 11p11.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20176 |
| Percent of cancer specimens with mutations: | 1.04 |
| Normal role description: | PTPRJ is a protein-tyrosine phosphatase that function as a signalling molecule responsible for regulating a variety of cellular processes, including cell growth, differentiation, mitosis, and oncogenesis. PTPRJ is present in all hematopoietic lineages, and has been shown to negatively regulate TCR signalling, possibly by interfering with the phosphorylation of PLCγ1 and Linker for Activation of T-Cells. It has also been found to dephosphorylate the PDGFβR, and may play a role in UV-induced signal transduction. Allelic loss of PTPRJ has been implicated in thyroid-, colon-, lung- and breast cancers, and loss of heterozygosity of the gene is commonly observed in meningiomas, where it normally functions as a tumour suppressor. |
| Commentary on involvement of protein in cancer: | 2 laryngeal samples/5 total UAT samples (mis-sense & silent), and 3/412 kidney samples were also mutated (Sanger COSMIC). Loss of heterozygosity of the gene has been found in 38% of human meningiomas. |